Vanguard Group Inc. Has $84.87 Million Holdings in Acorda Therapeutics, Inc. (ACOR)

Vanguard Group Inc. boosted its stake in Acorda Therapeutics, Inc. (NASDAQ:ACOR) by 4.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,308,160 shares of the biopharmaceutical company’s stock after purchasing an additional 168,571 shares during the period. Vanguard Group Inc. owned about 9.38% of Acorda Therapeutics worth $84,871,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. State of Wisconsin Investment Board purchased a new position in Acorda Therapeutics in the 2nd quarter worth approximately $630,000. AQR Capital Management LLC increased its stake in Acorda Therapeutics by 48.3% in the 1st quarter. AQR Capital Management LLC now owns 129,458 shares of the biopharmaceutical company’s stock worth $2,719,000 after purchasing an additional 42,154 shares during the period. Cambiar Investors LLC increased its stake in Acorda Therapeutics by 3.1% in the 2nd quarter. Cambiar Investors LLC now owns 861,331 shares of the biopharmaceutical company’s stock worth $16,968,000 after purchasing an additional 25,688 shares during the period. Whittier Trust Co. increased its stake in Acorda Therapeutics by 2.5% in the 2nd quarter. Whittier Trust Co. now owns 36,346 shares of the biopharmaceutical company’s stock worth $716,000 after purchasing an additional 895 shares during the period. Finally, HighTower Advisors LLC increased its stake in Acorda Therapeutics by 41.2% in the 1st quarter. HighTower Advisors LLC now owns 37,048 shares of the biopharmaceutical company’s stock worth $775,000 after purchasing an additional 10,819 shares during the period.

Acorda Therapeutics, Inc. (NASDAQ:ACOR) opened at 26.85 on Monday. The stock’s market capitalization is $1.25 billion. The stock’s 50 day moving average price is $24.89 and its 200 day moving average price is $20.30. Acorda Therapeutics, Inc. has a 1-year low of $13.60 and a 1-year high of $33.00.

WARNING: This story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.com-unik.info/2017/10/30/vanguard-group-inc-has-84-87-million-holdings-in-acorda-therapeutics-inc-acor.html.

ACOR has been the topic of a number of analyst reports. BidaskClub raised Acorda Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, July 7th. Jefferies Group LLC initiated coverage on Acorda Therapeutics in a research note on Monday, July 10th. They issued a “hold” rating and a $22.00 price target on the stock. Zacks Investment Research cut Acorda Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Acorda Therapeutics in a research note on Friday, July 28th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research note on Tuesday, August 29th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $24.06.

In other Acorda Therapeutics news, major shareholder Scopia Capital Management Lp purchased 766,201 shares of the firm’s stock in a transaction that occurred on Tuesday, August 29th. The stock was purchased at an average cost of $19.23 per share, with a total value of $14,734,045.23. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Barry E. Greene sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $21.57, for a total value of $215,700.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at $215,700. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by company insiders.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Want to see what other hedge funds are holding ACOR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

What are top analysts saying about Acorda Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit